BI 207127: Phase IIb data

Data from 20 evaluable treatment-naïve patients with chronic HCV genotype 1b infection in the open-label Phase IIb SOUND-C3 trial showed that 100% of patients who received once-daily BI 201335 plus twice-daily BI 207127 and ribavirin for 16 weeks achieved an SVR 4 weeks after the end of treatment. Full data from SOUND-C3 are expected this year. Boehringer also said it started the Phase III HCVerso 1 and HCVerso 2 trials evaluating once-daily 120 mg BI 201335 plus twice-daily 600 mg BI 207127 and ribavirin for 16 or 24 weeks in about 1,000 treatment-naïve patients with HCV genotype 1b infection. Data from the HCVerso trials are expected in late 2013. ...